Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Fochon Biosciences Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's current activity is restricted to 1 distinct examiner and 1 distinct art unit. This suggests a specific scope of active prosecution for the company's current applications. The concentration in 1 distinct art unit indicates that the company's current research and development efforts are focused on a specific area of biotechnology.
STOCKTON, LAURA LYNNE is the busiest examiner, overseeing 1 pending office action. This busiest examiner pending count of 1 represents the total pending workload for the company. The involvement of 1 distinct art unit means the company is currently interacting with this technical review group. This centralized prosecution model means that the company's immediate patent goals are subject to the review of 1 distinct examiner at the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOCKTON, LAURA LYNNE | 1 | 75.2% | +33.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998234 | COMPOUNDS AS BCL-2 INHIBITORS | STOCKTON, LAURA LYNNE | 22d |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17998234 | COMPOUNDS AS BCL-2 INHIBITORS | STOCKTON, LAURA LYNNE | 1626 | §112DP | Non-Final OA | 22d | Pending | Nov 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial